CN105377891A - Vegf拮抗剂在治疗儿童患者的脉络膜视网膜新生血管和通透性疾病中的应用 - Google Patents

Vegf拮抗剂在治疗儿童患者的脉络膜视网膜新生血管和通透性疾病中的应用 Download PDF

Info

Publication number
CN105377891A
CN105377891A CN201480039606.4A CN201480039606A CN105377891A CN 105377891 A CN105377891 A CN 105377891A CN 201480039606 A CN201480039606 A CN 201480039606A CN 105377891 A CN105377891 A CN 105377891A
Authority
CN
China
Prior art keywords
vegf antagonist
disease
vegf
dose
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480039606.4A
Other languages
English (en)
Chinese (zh)
Inventor
S·阿克赛诺夫
G·布莱恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN105377891A publication Critical patent/CN105377891A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F9/00821—Methods or devices for eye surgery using laser for coagulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Surgery (AREA)
  • Optics & Photonics (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201480039606.4A 2013-07-11 2014-07-09 Vegf拮抗剂在治疗儿童患者的脉络膜视网膜新生血管和通透性疾病中的应用 Pending CN105377891A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361845064P 2013-07-11 2013-07-11
US61/845,064 2013-07-11
PCT/IB2014/062978 WO2015004616A1 (en) 2013-07-11 2014-07-09 Use of a vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients

Publications (1)

Publication Number Publication Date
CN105377891A true CN105377891A (zh) 2016-03-02

Family

ID=51211282

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480039606.4A Pending CN105377891A (zh) 2013-07-11 2014-07-09 Vegf拮抗剂在治疗儿童患者的脉络膜视网膜新生血管和通透性疾病中的应用

Country Status (11)

Country Link
US (2) US20160168240A1 (https=)
EP (1) EP3019526A1 (https=)
JP (1) JP2016528202A (https=)
KR (1) KR20160029794A (https=)
CN (1) CN105377891A (https=)
AU (2) AU2014288837A1 (https=)
BR (1) BR112016000177A2 (https=)
CA (1) CA2917807A1 (https=)
MX (1) MX2016000384A (https=)
RU (1) RU2676274C2 (https=)
WO (1) WO2015004616A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109310756A (zh) * 2016-05-13 2019-02-05 奥美药业有限公司 新型血管生成素2，vegf双特异性拮抗剂
CN112040978A (zh) * 2017-11-16 2020-12-04 伊维希比奥公司 治疗或预防特发性息肉状脉络膜血管病变（ipcv）的方法
CN114845718A (zh) * 2019-12-19 2022-08-02 活跃生物技术有限公司 用于治疗与过度血管形成相关的眼部疾病的化合物
CN118085112A (zh) * 2024-04-29 2024-05-28 上海鼎新基因科技有限公司 抗多个vegf家族蛋白的融合蛋白及其应用

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2494108C2 (ru) 2006-04-07 2013-09-27 Аерпио Терапетикс, Инк. Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
ES2726946T3 (es) 2009-07-06 2019-10-10 Aerpio Therapeutics Inc Derivados de benzosulfonamida, composiciones de los mismos y su uso en la prevención de la metástasis de las células cancerosas
WO2013056240A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
EP3116503A4 (en) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
CN106456757A (zh) * 2014-05-12 2017-02-22 福尔密孔股份公司 含有vegf拮抗剂的预填充塑料注射器
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
ES2894802T3 (es) 2015-09-23 2022-02-15 Aerpio Pharmaceuticals Inc Activadores de Tie-2 para su uso en el tratamiento de la presión intraocular
CN108290004A (zh) * 2015-11-18 2018-07-17 福尔密孔股份公司 含有vegf拮抗剂的预填充塑料注射器
WO2017084616A1 (en) * 2015-11-19 2017-05-26 Zhuhai Tairuishang Biopharm Ltd. Methods and compositions for binding vegf
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
BR112019001206A2 (pt) 2016-07-20 2019-06-25 Aerpio Therapeutics Inc anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss)
US20190388522A1 (en) * 2017-01-25 2019-12-26 Iconic Therapeutics, Inc. Methods for treating disorders associated with angiogenesis and neovascularization
BR112019023061A2 (pt) * 2017-05-01 2020-06-09 Ojai Retinal Tech Llc processo para prevenir ou tratar miopia
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
EP3962482A4 (en) 2019-04-29 2023-01-11 EyePoint Pharmaceuticals, Inc. TIE 2 ACTIVATORS FACING THE SCHLEMM CHANNEL
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
RU2762991C1 (ru) * 2021-09-06 2021-12-24 федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ лечения макулярного отека вследствие окклюзии ветви центральной вены сетчатки в сочетании с ретинальной артериолярной макроаневризмой
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
TW202525324A (zh) * 2023-08-17 2025-07-01 大陸商信達生物製藥（蘇州）有限公司 治療年齡相關性黃斑變性和糖尿病性黃斑水腫的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1404297B1 (en) 2001-06-12 2011-04-27 The Johns Hopkins University School Of Medicine Reservoir device for intraocular drug delivery
WO2005110374A1 (en) 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
EP1767546B1 (en) 2004-06-08 2012-03-07 Chengdu Kanghong Biotechnologies Co., Ltd. Angiogenesis-inhibiting chimeric protein and the use
US20070072933A1 (en) * 2005-09-26 2007-03-29 Peyman Gholam A Delivery of an ocular agent
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
EP2247289A4 (en) * 2008-02-21 2011-05-04 Ista Pharmaceuticals OPHTHALMIC NSAIDS AS ADJUVANTIES
WO2010045506A2 (en) * 2008-10-16 2010-04-22 Kathleen Cogan Farinas Sustained drug delivery system
BRPI0921469B1 (pt) 2008-11-03 2022-01-18 Molecular Partners Ag Proteínas de ligação que inibem a interação com o receptor de vegf-a, composição farmacêutica
MX337922B (es) * 2008-12-16 2016-03-28 Valeant Pharmaceuticals Int Combinacion de terapia fotodinamica y agentes anti-vegf en el tratamiento de neovasculatura coroidal indeseable.
AU2010208046B2 (en) 2009-01-29 2014-10-02 Forsight Vision4, Inc. Posterior segment drug delivery
EP3028707A1 (en) * 2009-05-01 2016-06-08 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
RU2469734C2 (ru) * 2010-09-02 2012-12-20 Григорий Владимирович Пантелеев Лечебное средство для лечения расстройств аккомодаций "stiak"

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
FRANK G HOLZ等: "VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion：6-month results of the phase III GALILEO study", 《BR J OPHTHALMOL》 *
JOSEPH D.BENEVENTO等: "Toxoplasmosis associated neovascular lesions treated successfully with ranibizumab and anti-parasitic therapy", 《ARCH OPHTHALMOL》 *
JUNG HYUN JANG等: "Photodynamic Therapy Combined with Intravitreal Bevacizumab in a Patient with Choroidal Neovascularization Secondary to Choroidal Osteoma", 《KOREAN J OPHTHALMOL》 *
K WEISS等: "Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumab", 《NATURE》 *
LIN KRISTIE L等: "Prospects for Treatment of Pediatric Vitreoretinal Diseases with Vascular Endothelial Growth Factor Inhibition", 《SEMINARS IN OPHTHALMOLOGY》 *
OSCAR RUIZ-MORENO等: "Long-term outcomes of intravitreal ranibizumab for choroidal neovascularization secondary to Best’s disease:3-year follow-up", 《ACTA OPHTHALMOLOGICA》 *
PEARSE A. KEANE等: "Development of Anti-VEGF Therapies for Intraocular Use: A Guide for Clinicians", 《JOURNAL OF OPHTHALMOLOGY》 *
PETER GOODWIN 等: "Ranibizumab for coloboma-related choroidal neovascular membrane in a child", 《JOURNAL OF AAPOS》 *
RADHA P.KOHLY等: "Management of pediatric choroidal neovascular membranes with intravitreal anti-VEGF agents：a retrospective consecutive case series", 《CAN J OPHTHALMOL》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109310756A (zh) * 2016-05-13 2019-02-05 奥美药业有限公司 新型血管生成素2，vegf双特异性拮抗剂
CN109310756B (zh) * 2016-05-13 2022-06-28 奥美药业有限公司 新型血管生成素2，vegf双特异性拮抗剂
CN112040978A (zh) * 2017-11-16 2020-12-04 伊维希比奥公司 治疗或预防特发性息肉状脉络膜血管病变（ipcv）的方法
CN114845718A (zh) * 2019-12-19 2022-08-02 活跃生物技术有限公司 用于治疗与过度血管形成相关的眼部疾病的化合物
CN118085112A (zh) * 2024-04-29 2024-05-28 上海鼎新基因科技有限公司 抗多个vegf家族蛋白的融合蛋白及其应用

Also Published As

Publication number Publication date
AU2017203923A1 (en) 2017-07-06
WO2015004616A1 (en) 2015-01-15
JP2016528202A (ja) 2016-09-15
EP3019526A1 (en) 2016-05-18
RU2676274C2 (ru) 2018-12-27
CA2917807A1 (en) 2015-01-15
AU2017203923B2 (en) 2018-10-18
US20180194835A1 (en) 2018-07-12
US20160168240A1 (en) 2016-06-16
AU2014288837A1 (en) 2015-12-10
RU2016104397A (ru) 2017-08-16
KR20160029794A (ko) 2016-03-15
BR112016000177A2 (pt) 2017-12-12
RU2016104397A3 (https=) 2018-05-31
MX2016000384A (es) 2016-04-29

Similar Documents

Publication Publication Date Title
RU2676274C2 (ru) Применение антагониста vegf при лечении хориоретинальных неоваскулярных нарушений и нарушений проницаемости у педиатрических пациентов
US20250268983A1 (en) Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders
JP2015528454A (ja) 眼血管増殖性疾患の処置におけるｖｅｇｆアンタゴニストの使用
JP2016523956A (ja) 未熟児網膜症の治療におけるｖｅｇｆアンタゴニストの使用
EP3010525A1 (en) Use of a vegf antagonist in treating choroidal neovascularisation
JP2016522250A (ja) 黄斑浮腫の治療におけるｖｅｇｆアンタゴニストの使用
US11944663B2 (en) Method for treating angiogenic eye disorders using VEGF antagonists
WO2014203181A1 (en) Treatment of polypoidal choroidal vasculopathy
TW201904610A (zh) 用於治療新生血管型青光眼之非抗體vegf拮抗劑
EP4028128A1 (en) Methods for treating ocular diseases
JP2023550458A (ja) 眼性疾患を治療する方法における使用のためのｖｅｇｆアンタゴニスト

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160302